PAPWORTH HOSPITAL NHS FOUNDATION TRUST

Their core work

Papworth Hospital (now Royal Papworth Hospital) is the UK's leading specialist cardiothoracic hospital, based in Cambridge. It provides advanced clinical care in heart and lung disease and participates in EU-funded research as a clinical partner, contributing patient cohorts, clinical trial infrastructure, and cardiology expertise. Their H2020 involvement centres on translational cardiovascular research — specifically drug repurposing trials for acute myocardial infarction — alongside selective participation in health data analytics projects.

What they specialise in

How they've shifted over time

Papworth's H2020 trajectory shows a consistent core in cardiovascular clinical research, bookended by the RITA-MI proof-of-concept (2016–2018) and its larger Phase 2 follow-up RITA-MI 2 (2021–2026). Between these, they briefly diversified into health data analytics via Track and Know (2018–2020), suggesting an interest in digital health applications alongside their primary clinical mission. The progression from ERC proof-of-concept to a full Phase 2 randomised trial signals growing investment in the rituximab-for-heart-attack hypothesis.

Papworth is deepening its commitment to immunotherapy-based cardiac treatments, advancing from early proof-of-concept to formal Phase 2 clinical trials — expect continued focus on translational cardiology research.

How they like to work

Papworth exclusively participates as a partner, never as coordinator — consistent with its role as a specialist clinical site contributing patients, trial infrastructure, and medical expertise to research-led consortia. With 28 unique partners across 14 countries from just 3 projects, they join broad European consortia rather than small bilateral collaborations. This profile suggests a reliable clinical partner that brings NHS hospital credibility and patient access without seeking project leadership overhead.

Despite only 3 projects, Papworth has collaborated with 28 distinct partners across 14 countries, reflecting participation in large multinational consortia rather than tight bilateral work. Their network spans broadly across Europe with no single dominant geographic cluster.

What sets them apart

Papworth is the UK's premier specialist heart and lung hospital, offering something few academic or industrial partners can: direct access to cardiothoracic patient populations within an NHS clinical setting. Their sustained involvement in the RITA-MI programme demonstrates genuine institutional commitment to a specific therapeutic hypothesis (rituximab for myocardial infarction), not just opportunistic project participation. For consortium builders, they offer clinical trial site capability with the credibility and regulatory infrastructure of a major NHS Foundation Trust.

Highlights from their portfolio

• RITA-MI 2
  Largest-funded project (€315K) and a Phase 2 placebo-controlled randomised clinical trial — represents the maturation of an earlier proof-of-concept into a rigorous drug repurposing study.
• RITA-MI
  ERC Proof-of-Concept project that originated the rituximab-for-heart-attack hypothesis, seeding a research line that continued for a decade.
• Track and Know
  Only non-cardiac project, showing Papworth's willingness to contribute healthcare data expertise to cross-sector big data initiatives.